CEL-SCI to Present New Multikine Data at Major Otolaryngology Congress
Event summary
- CEL-SCI's CSO Dr. Eyal Talor to deliver keynote at Otorhinolaryngology 2026 in Rome on October 26–27, 2026
- Presentation will reveal new Phase 3 study findings on Multikine's tumor biomarkers and patient selection
- Data supports upcoming 212-patient U.S. Confirmatory Registration Study with 97% statistical power
- Multikine previously showed 73% 5-year survival rate vs. 45% in standard care alone
- Company has administered Multikine to over 740 patients with excellent safety profile
The big picture
CEL-SCI's invitation to present at this prestigious international congress signals growing recognition of its biomarker-driven approach to head and neck cancer treatment. The company's focus on pre-surgical immunotherapy aligns with broader industry trends toward personalized cancer treatment strategies. With over 740 patients treated and strong Phase 3 results, Multikine represents one of the most advanced neoadjuvant immunotherapies in development.
What we're watching
- Data Validation
- Whether new biomarker findings will validate Multikine's survival benefit in the upcoming registration study
- Regulatory Pathway
- The pace at which FDA review progresses for Multikine's Orphan Drug designation and potential approval
- Market Differentiation
- How CEL-SCI positions Multikine against emerging neoadjuvant immunotherapy competitors
Related topics